Japanese encephalitis vaccine-facilitated dengue virus infection-enhancement antibody in adults by unknown
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Abstract
Background: Dengue virus (DENV) and Japanese encephalitis virus (JEV) belong to the genus Flavivirus, and infection
with a virus within this genus induces antibodies that are cross-reactive to other flaviviruses. Particularly in DENV
infection, antibodies to DENV possess two competing activities: neutralizing activity and infection-enhancing activity.
These antibody activities are considered central in modulating clinical outcomes of DENV infection. Here, we determined
the neutralizing and infection-enhancing activity of DENV cross-reactive antibodies in adults before and after JE
vaccination.
Methods: Participants were 77 Japanese adults who had received a single dose of inactivated Vero cell-derived JE
vaccine. A total of 154 serum samples were obtained either before or approximately a month after a single dose of JE
vaccination. The antibody-dependent enhancement (ADE) activity to each of four DENV serotypes and the neutralizing
activities to DENV and to JEV were determined in each of the serum samples by using baby hamster kidney (BHK) cells
and FcγR-expressing BHK cells.
Results: A total of 18 post-JE immunization samples demonstrated cross-reactivity to DENV in an anti-DENV IgG ELISA.
DENV neutralizing antibodies were not detected after JE vaccination in this study. However, undiluted post-JE vaccination
serum samples from 26 participants demonstrated monotypic and heterotypic ADE activity to DENV. ADE activity was
also observed in 1:10-diluted samples from 35 of the JE vaccine recipients (35/77, 45 %).
Conclusion: In summary, JE vaccination induced DENV cross-reactive antibodies, and at sub-neutralizing levels, these
DENV cross-reactive antibodies possess DENV infection-enhancement activity. The results also indicate that cross-reactivity
to DENV is associated with high levels of JEV neutralizing antibodies and, the DENV cross-reactivity is further facilitated by
JE vaccination.
Background
Dengue virus (DENV) infection mainly occurs in trop-
ical and subtropical areas. It is estimated that there are
390 million dengue infections annually, and recently the
number of dengue cases has increased exponentially
worldwide [1]. Although DENV had not previously been
endemic in Japan, a dengue outbreak occurred in 2014,
resulting in 162 autochthonous dengue cases [2]. DENV
and Japanese encephalitis virus (JEV) co-circulate in
many Asian countries [3]. JE occurs in East, South, and
Southeast Asia. Both DENV and JEV cause serious pub-
lic health threats and are the leading causes of
hospitalization and death in children in vast regions of
Asia. These viruses belong to the genus Flavivirus, and
infection with a virus within this genus induces anti-
bodies that are cross-reactive to other flaviviruses [4–6].
Particularly in DENV infection, antibodies induced has
been demonstrated to possess 2 competing activities:
neutralizing and infection-enhancement activities. Anti-
bodies with DENV infection-enhancement activities are
speculated to contribute to disease severity by a mech-
anism known as antibody-dependent enhancement
(ADE). This mechanism leads to high levels of infection
and the production of progeny viruses in DENV target
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cells, the FcγR-expressing monocytes and macrophages.
Infection-enhancement activity also hampers virus neu-
tralizing activity [7, 8].
DENV and JEV are antigenically related viruses. Cross-
reactivity was observed in vitro between both of these
viruses [4, 5]. An improved understanding of pre-
existing immunity to JEV and the implications of this
flavivirus-primed immunity in subsequent infection are
important as DENV outbreaks often occur in JEV co-
endemic areas as well as in areas where JE immunization
is routine. Vaccination also induces cross-protection
between JEV and viruses from the same Japanese en-
cephalitis serocomplex-group including West Nile virus
(WNV), and Murray Valley encephalitis virus in animal
models [9, 10]. Natural DENV and JEV infection or JE
vaccine immunization, could each contribute to the
overall immune background of an individual in areas
where both DENV and JEV co-circulate [11, 12]. There-
fore, it is particularly challenging to define the associ-
ation between pre-existing immunity to JEV and dengue
clinical severity in DENV endemic areas. Although
cross-protection against DENV was observed in mice in-
oculated with JE vaccine, previous investigators have also
demonstrated that flavivirus antisera enhance DENV-2
infection [13]. These antibodies with neutralizing activity
(NA) against JEV induced by either a prior JEV infection
or by JE vaccination also possess neutralizing activity to
DENV in vitro [5, 14]. However, other investigators
reported absence of cross-protective neutralizing anti-
bodies of viruses from the same serocomplex group
(JEV and WNV) [15, 16]. Pre-existing immunity to JEV
was also associated with an increased occurrence of
symptomatic DENV infection [12]. Because non-FcγR
bearing cells were used in these studies, the sum of neu-
tralizing activity and infection-enhancement activity, and
the ADE activity of these antibodies at subneutralizing
levels, has not been determined. Thus, a better under-
standing on cross-reactive immunity induced with JE
vaccination, particularly the infection-enhancement and
neutralizing activities of the cross-reactive antibodies, is
expected to facilitate development of effective vaccin-
ation and preventive strategies for flavivirus disease con-
trol, including DENV and JEV infection [17–19].
Potential interactions between flaviviruses have sig-
nificant public health implications because areas with
high JE vaccine coverage and JEV circulation are also
frequently areas with a high dengue disease burden
[12]. With the rapid expansion of DENV endemic areas
and emergence in previously non-endemic areas, an
improved understanding of the pre-existing immunity
against JEV and of the potential implications for subse-
quent DENV exposure is necessary. In this study, we
used BHK and FcγR-expressing BHK cells to determine
DENV cross-reactive activities in antibodies of adults




Serum samples were obtained from 77 Japanese adults
(mean age = 38.1 ± 10.7; male:female ratio = 1.8:1) who
received a single dose of Vero cell-derived inactivated JE
vaccine (JEBIK V®, BIKEN, Japan) at the National Center
for Global Health and Medicine (NCGM), Tokyo Japan
[20]. These serum samples were obtained before vaccin-
ation and 3–5 weeks after JE vaccination during the
period of 2009–2011 (Additional file 1 Table S1), during
which no local DENV outbreaks were reported [20].
Samples were collected at the NCGM, and all laboratory
tests were performed at the National Institute of Infec-
tious Diseases, Japan (NIID). The study protocols were
approved by the NCGM and NIID Institutional Ethics
Review Board (no. 473). All samples were de-identified
prior to tests conducted at the NIID. All serum samples
were heat-inactivated at 56 °C for 30 min prior to use.
Of the 79 participants who received the JE vaccine, 50
participants had previous immunization history against
JE, however the JE vaccination history for the other 29
participants was unknown. Samples from 2 participants
were excluded from this study because of insufficient
sample volume. Thus, samples from 77 participants were
used in this study. Because the travel history of the
participants was incomplete, that data were excluded
from this study.
Determination of the levels of anti-DENV IgM and IgG
antibodies by ELISA
The amount of DENV-specific IgM antibody in the
serum samples was determined using an IgM capture
ELISA kit (Dengue Virus IgM Capture DxSelect ELISA
Kits, Focus Diagnostics, CA, USA) according to the
manufacturer’s instructions. Dengue IgG ELISAs (Den-
gue IgG Indirect ELISA, Panbio, Queensland, Australia
and Dengue ELISA IgG, Vircell, Granada, Spain) were
used according to manufacturer’s instructions for the
detection of anti-DENV IgG antibody. The presence of
DENV cross-reactive IgG antibody was defined as posi-
tive detection by at least one of these kits [21]. The
index value of anti-DENV IgM and IgG ELISA was de-
termined by dividing the average OD of each sample by
the cut-off value according to manufacturers’ instruc-
tion. The cut-off value was determined by multiplying
the average OD of the calibrator by the calibration fac-
tor provided by the manufacturer. Index values of <0.9,
0.9–1.1, and, >1.1 were considered negative, equivocal,
and positive, respectively. Equivocals were regarded as
negative.
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Determination of the levels of anti-JEV IgG antibody by
ELISA
Anti-JEV IgG antibody in samples was determined by
using an in-house JEV-specific IgG ELISA. A 96-well
ELISA plate (NUNC, Thermo Scientific, USA) coated
overnight at 4 °C with JEV antigen was used. After wash-
ing four times with 1× Dulbecco’s phosphate buffered
saline, no calcium, no magnesium (1× DPBS (−)) (Life
Technologies, CA, USA), and 200 μl of 0.1 % casein in
1× DPBS (−) was added into each well, and the plate
was incubated at 37 °C for 2 h. After washing, 100 μl of
the ten-folds diluted serum samples (1:100 to 1:25,600)
were added and the plates were incubated at 37 °C for
1 h. After washing, 100 μl of horseradish peroxidase
(HRP)-conjugated anti-human IgG was then added into
each well, and the plate was incubated at 37 °C for 1 h.
After further washing, 100 μl of tetramethylbenzidine
(TMB) solution was added and reactions were termi-
nated after 10 min with 100 μl of stop solution (1 N
H2SO4). The ELISA endpoint corresponded to the high-
est dilution of the serum sample in which the positive to
negative (P/N) ratio of the O.D. values was greater than
2. Thus, samples of P/N ratio of >2 were interpreted as
positive.
Viruses and cell lines
DENV-1 (01–44 strain), DENV-2 (TLC-30 strain),
DENV-3 (NRT 09–34 strain), and DENV-4 (08–11
strain) were used in neutralizing and ADE assays against
DENV [22]. JEV (Beijing-1 strain) was used in the JEV
neutralizing assays. Baby hamster kidney (BHK) cells
(Japan Health Science Research Resources Bank, Japan),
FcγR-expressing BHK cells and Vero cells (African green
monkey kidney epithelial cells) were used [21, 22]. BHK
cells and Vero cells were cultured in Eagle’s Minimum
Essential Medium (EMEM, Sigma), supplemented with
heat-inactivated 10 % fetal bovine serum (FBS, Sigma)
without antibiotics. The cells were maintained at 37 °C
in 5 % CO2. FcγR-expressing BHK cells were cultured in
EMEM, supplemented with heat-inactivated 10 % FBS
and 0.5 mg/ml neomycin (G418, Roche Diagnostics
GmbH Mannheim, Germany) at 37 °C in 5 % CO2.
JEV and DENV neutralization assay
Neutralization tests against JEV were performed by using
the 50 % focus reduction neutralization test method
(FRNT50) as previously reported [20]. Neutralization tests
against DENV were performed by the 50 % plaque reduc-
tion neutralization test (PRNT50) method as previously re-
ported [22]. The presence of a NA titer was defined as the
demonstration of a 50 % or greater plaque reduction at a
titer of ≥1:10. The values of neutralizing antibody titers of
below limit of detection (<1:10) were considered equal to
the limit of detection divided by the square root of 2.
Antibody-dependent enhancement (ADE) assay for DENV
The presence of ADE activity was determined by plaque
assay. A total of 154 serum samples was diluted to 1:10
in EMEM supplemented with 10 % FBS. DENV were
prepared at titers of 2000 PFU/ml for ADE assays using
10-fold-diluted serum samples. Virus-antibody mixtures
were prepared by mixing 25 μl each of each DENV sero-
type with 25 μl of diluted serum samples. A control mix-
ture was prepared by combining 25 μl of each DENV
serotype with 25 μl of EMEM supplemented with 10 %
FBS. For samples that demonstrated ADE activity at a 1:10
dilution, further tests was performed using undiluted serum
samples [23]. Infection enhancement (measured as ADE
activity) was tested using serum samples that had been
diluted 1:10. ADE activity was defined as fold-enhancement
values greater than the cut-off value (cut-off value =
mean plaque count FcγR-expressing BHK cells without
the addition of human serum using + 3 s.d.)/(mean
plaque count of FcγR-expressing BHK cells without the
addition of human serum + 3). The presence of ADE
activity was defined as having fold enhancement values
of >1.9 for DENV-1, DENV-2, and DENV-3 or of >1.8
for DENV-4.
Statistical analyses
The tabulation, management, and analyses of data were
performed using Microsoft Excel. Study outcomes were
compared by t-tests, chi-squared tests, Fisher’s exact
tests and Pearson’s correlation test [24, 25]. Geometric
datasets were used for parametric analyses.
Results
Increase in positive rates of anti-DENV IgG after JE
vaccination
The overall serological cross-reactivity to DENV in
adult JE vaccine recipients was examined by anti-DENV
IgG ELISAs. ELISA was performed using 154 serum
samples obtained from participants pre- and post-JE
vaccination (Additional file 1: Table S1). Prior to JE vac-
cination, seropositive rate of DENV IgG seropositivity
was 9 % (3/34) in samples with no JE neutralizing anti-
bodies, and was 21 % (9/43) in samples with JEV neu-
tralizing antibodies. After JE vaccination, anti-DENV
IgG antibodies was detected in 20 % (1/5) samples
without JEV neutralizing activity (PRNT50 < 1:10), and
in 40 % (29/72) samples with JEV neutralizing activity
(Fig. 1a). Overall, the number of participants that dem-
onstrated DENV cross-reactive IgG antibody increased
from 12 to 30 after JE vaccination. DENV reactivity was
defined as positive if a sample was determined to be
positive by either of the two ELISA platforms used
(Additional file 2: Table S2). The anti-DENV IgG index
values were higher after JE vaccination (t-test p < 0.01)
(Fig. 1b-c). Thus, the results indicate that the increase
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in DENV cross-reactive IgG antibodies after JE vaccin-
ation moderately correlated with the levels of JEV neu-
tralizing activity.
JE vaccination increased ADE activity to all four DENV
serotypes
Vacinee serum samples at 1:10 dilutions were examined
for ADE activity against each of the four DENV serotypes
(DENV 1–4) by using FcγR-expressing BHK cells. The
ADE activity against DENV-1 was 6 % (5/77) before vac-
cination and 18 % (14/77) after vaccination. For DENV2,
3 % (2/77) had ADE activity before JE vaccination and
21 % (16/77) after vaccination, for DENV3, 14 % (11/77)
had ADE activity before vaccination and 31 % (24/77)
after vaccination, and for DENV4, 13 % (10/77) had ADE
activity before vaccination and 34 % (26/77) after vaccin-
ation. The number of serum samples observed with ADE
activity to each of the four DENV serotypes significantly
increased after JE vaccination (Fisher’s exact test): DENV-
1 (p = 0.03), DENV-2 (p < 0.01), DENV-3 (p < 0.01), and
DENV-4 (p < 0.01) (Table 1). The results indicate that
cross-reactive activity to DENV increase with JE vaccin-
ation and these activities possess ADE activity to DENV.
Increase in overall ADE activity to DENV in JE vaccine
recipients
The ADE activity among the four DENV serotypes and
the levels of JEV neutralizing activity before and after
vaccination were also examined. Serum samples were
split into three groups: Group A, JE vaccine recipients
that did not possess ADE activity against DENV before
or after JE vaccination; Group B, JE vaccine recipients
that exhibited ADE activity to DENV only after JE vac-
cination; and Group C, JE vaccine recipients that exhib-
ited ADE activity to DENV both before and after JE
vaccination. JEV NA titers of subjects in Group A were
significantly lower before and after vaccination than
those of subjects who demonstrated ADE activity to
DENV after JE vaccination (Group B and Group C). The
increase in JEV neutralizing activity levels in participants
with ADE activity to DENV after JE vaccination was sig-
nificantly higher in participants that demonstrated ADE
after vaccination, in comparison to the participants that
did not exhibit ADE activity to DENV (Group B = 578 ±
803, t-test p < 0.01; Group C = 980 ± 1422, t-test p <
0.01). Additionally, the number of participants that dem-
onstrated DENV IgG cross-reactive antibodies increased
in all groups (Groups A–C). Specifically, the anti-DENV
a b c
Fig. 1 Dengue virus (DENV) cross-reactive antibodies facilitated by Japanese encephalitis virus (JEV) vaccination. a Percentage of vaccinees with
anti-DENV IgG antibodies. Open bars indicate serum samples with no neutralizing JEV antibodies, and closed bars indicate samples with ≥ 1:10
neutralizing antibody titers to JEV. Serum samples obtained before (b open circles) and after (c closed circles) JE vaccination. An ELISA index value
above 1.1 was considered positive for DENV IgG antibodies
Table 1 Number of serum samples with antibody-dependent enhancement (ADE) activitya to each of the 4 dengue virus (DENV)
serotypes, pre- and post-Japanese encephalitis (JE) vaccination
Samples Number of serum samples that demonstrated ADE activity (Percentage of samples with ADE activity)
DENV-1 DENV-2 DENV-3 DENV-4
Pre-JE vaccination
(n = 77)
5 (6 %) 2 (3 %) 11 (14 %) 10 (13 %)
Post-JE vaccination
(n = 77)
14 (18 %) 16 (21 %) 24 (31 %) 24 (31 %)
aThe number of serum samples observed with ADE activity to each of the four DENV serotypes significantly increased after JE vaccination (Fisher’s exact test):
DENV-1 (p = 0.03), DENV-2 (p < 0.01), DENV-3 (p < 0.01), and DENV-4 (p < 0.01)
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IgG levels increased significantly after JE vaccination in
Group B as compared to those in Group A (Group
APOST = 0.8 ± 0.3, Group BPOST = 1.5 ± 0.7; t-test p <
0.01), with Group B demonstrating 15 DENV serocon-
versions after JE vaccination (Table 2).
Notably, the JE vaccine recipients in Group C dem-
onstrated significantly higher anti-DENV IgG levels
both pre- (t-test; p < 0.01 against Groups A and B)
and post-JE vaccination (t-test; p < 0.01 against
Groups A and B) than those in groups A and B.
Group C also demonstrated a higher percentage of JE
vaccine recipients with ADE activity against two or
more DENV serotypes (73 %, 11/15), as compared to
Group B (50 %, 10/20). The results, together with the
observed higher JEV neutralizing activity in serum
samples from Group C, suggested that pre-existing
JEV immunity increased the overall immune reactivity
against JEV and DENV due to facilitation by JE vac-
cination (Table 2).
Of the 23 participants who demonstrated anti-IgG
DENV cross-reactive antibodies after JE vaccination, all
had serum samples that were negative for anti-DENV
IgM (data not shown), indicating that the increase in
anti-DENV IgG levels after JE vaccination was not due
to a recent DENV infection.
ADE activity to DENV in undiluted serum samples after JE
vaccination
The ADE activity of the serum samples with demon-
strated ADE activity against DENV at 1:10 dilutions
after JE vaccination were also used to determine the
ADE activity in undiluted samples on FcγR-expressing
BHK cells. Out of the 35 serum samples that demon-
strated ADE activity to DENV at a 1:10 dilution, 26 un-
diluted serum samples also demonstrated ADE activity
to DENV. The fold-enhancement of undiluted serum
samples ranged from 2.5-fold to 14.5-fold. Of these 26
serum samples, 10 serum samples demonstrated ADE
activity against a single serotype, 4 serum samples dem-
onstrated ADE activity against two DENV serotypes,
and 12 serum samples demonstrated ADE activity
against three or more DENV serotypes, at undiluted
levels (Table 3). Serum dilution decreases the amount
of antibodies, and thus, some samples exhibited ADE
activity upon serum dilution. Using undiluted serum
samples, the results indicated that these serum samples
possessed the potential to enhance DENV infection at
biological levels.
Absence of NA to DENV in serum samples collected from
JE vaccine recipients
The DENV neutralizing activity against all four serotypes
of the serum samples obtained from 77 JE vaccine recip-
ients was determined using BHK and FcγR-expressing
BHK cells. Out of the 77 JE vaccine recipients, only one
(vaccine recipient #73) exhibited neutralizing activity
against DENV-1 in the serum samples collected both
before and after JE vaccination (BHK cells, PRNT50
DENV1PRE = 160, PRNT50 DENV1POST = 160; FcγR-
expressing BHK cells, PRNT50 DENV1PRE = 40, PRNT50
DENV1POST = 40). Subject #73 also exhibited ADE to
DENV-1, pre- and post-JE vaccination, from serum
Table 2 Antibody-dependent enhancement (ADE) activity against the four dengue virus (DENV) serotypes in each of the samples
obtained from the 77 participants, pre- and post-Japanese encephalitis (JE) vaccination and corresponding JEV neutralizing antibody
(NA) levels
ADE activity in each of the serum samples to four DENV serotypes n JEV NA titera
(Mean JEV NA titer ± s.d.)
Pre-vaccination Post-vaccination
(A) Absence of ADE activity to DENV, both before and after JE vaccination 40 19 ± 29 153 ± 419
(B) Presence of ADE activity to DENV after JE vaccination only
1. ADE activity to ≥3 DENV serotypes 6 98 ± 124 1130 ± 1199
2. ADE activity to two DENV serotypes 4 91 ± 153 500 ± 592
3. ADE activity to one DENV serotype 10 47 ± 64 277 ± 372
Total 20 71 ± 101b 578 ± 803b
(C) Presence of ADE activity to DENV both before and after JE vaccination
1. ADE activity to ≥3 DENV serotypes 10 96 ± 122 1325 ± 1644
2. ADE activity to two DENV serotypes 1 40 80
3. ADE activity to one DENV serotype 4 53 ± 74 341 + 346
Total 15 81 ± 106b 980 + 1422b
aJEV NA titers were determined by using a 50 %-focus-reduction neutralization test
bThe increase in JEV NA levels in participants with ADE activity to DENV after JE vaccination was significantly higher in participants that demonstrated ADE after
vaccination (Group B = 578 ± 803, t-test p <0.01; Group C = 980 ± 1422, t-test p < 0.01) in comparison to those that did not demonstrate ADE activity to DENV
(Group A). Samples from 2 patients were excluded due to insufficient volume for the ADE assay
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Table 3 Antibody-dependent enhancement (ADE) activity against four dengue virus (DENV) serotypes in post-Japanese encephalitis (JE) vaccination serum samples that were




Fold enhancement to DENVa ADE activity to
number of DENV
serotypes
DENV-1 DENV-2 DENV-3 DENV-4
Undiluted 1:10-dilution Undiluted 1:10-dilution Undiluted 1:10-dilution Undiluted 1:10-dilution Undiluted 1:10-dilution
3 –b – – – – – 3.1 2.5 1 1
9 – – – – – – 2.2 1.9 0 1
11 4.5a 2.3 3.2 4.0 4.1a 2.9 2.3 2.7 3 4
13 13.0 2.8 4.0 2.8 5.9 2.1 4.5 2.8 4 3
19 – – – – 4.4 2.6 – – 1 1
202 14.5 2.6 2.8 3.6 5.3 2.5 3.3 2.4 4 4
211 – – 4.2 2.6 4.3 3.5 4.9 2.8 3 3
22 3.5 2.0 – – – – – – 1 1
313 2.5 3.0 6.6 4.8 2.7 3.2 4.7 2.4 2 4
321 – – – – 2.5 2.5 – – 0 1
33 6.0 2.5 2.5 3.8 4.1 3.9 4.4 2.2 4 4
43 – – 5.1 2.8 4.9 4.8 6.6 1.8 3 2
47 – – – – 3.2 3.3 1.6 2.3 0 2
49 – – – – 3.9 2.3 – – 1 1
512 6.7 2.6 – – 5.0 2.6 3.3 2.3 3 3
53 – – – – 3.9 2.0 – – 1 1
54 – – – – 5.0 3.5 – – 1 1
573 6.7 2.2 5.5 2.0 4.5 2.7 3 3
58 4.0 1.9 1.5 3.2 4.1 3.2 3.4 3.8 3 3
593 4.3 4.2 1.2 2.5 4.0 3.9 1.0 3.4 2 4
61 7.3 2.1 – – – – – – 1 1
732 – – 0.4 2.3 4.1 3.5 1.3 3.5 1 3
77 – – – – 6.3 4.0 3.3 1.8 2 1
781 – – – – 2.0 2.2 – – 0 1
79 2.0 2.2 1.1 3.6 5.0 6.7 3.8 2.7 2 4
80 4.0 2.1 2.5 2.5 5.4 3.2 – – 3 3
85 – – – – – – 6.2 2.6 1 1
861 1.7 2.4 1.0 3.3 2.9 4.6 2.3 2.5 0 4













Table 3 Antibody-dependent enhancement (ADE) activity against four dengue virus (DENV) serotypes in post-Japanese encephalitis (JE) vaccination serum samples that were
diluted 1:10 or left undiluted (Continued)
93 – – – – 3.1 3.2 1.9 2.4 0 2
941 – – – – – – 5.8 2.6 1 1
951 – – – – – – 2.1 2.1 0 1
961 – – 4.0 2.0 3.8 3.1 3.8 5.2 3 3
100 – – – – – – 2.4 2.1 0 1
110 – – – – 4.9 2.8 3.4 2.2 2 2
Total number of samples 12 14 11 16 20 24 17 24
aItalics indicates the presence of ADE activity
b–denotes an absence of ADE activity at a 1:10 sample dilution to the tested DENV serotype. Assessments of ADE activity in undiluted samples were not performed in samples that did not demonstrate ADE activity at
the 1:10 dilution













dilutions of 1:160 to 1:2560. Pre- and post-JE vaccination
fold-enhancement values to DENV1 of subject #73
ranged from 2.0 to 5.9. The results suggest that partici-
pant #73 was previously infected with DENV-1. With
the exception of participant #73, the absence of DENV
neutralizing activity against all four DENV serotypes in
our samples suggests that prior exposure to DENV was
likely limited in the JE vaccine recipients of this study.
Thus, although the ADE activity increased, DENV cross-
reactive NAs were overall absent in this study.
Anti-JEV IgG endpoints were higher than anti-DENV IgG
endpoints in samples that were positive for anti-DENV IgG
Twelve of the serum samples collected prior to JE vac-
cination and positive for anti-DENV IgG antibodies were
selected, and the anti-JEV IgG ELISA endpoints of these
12 serum samples were compared with their corre-
sponding anti-DENV IgG ELISA endpoints (Additional
file 3: Table S3). The JEV endpoints in all 12 samples
were higher than those for DENV (mean JEV endpoint
= 9600 ± 9887, mean DENV endpoint = 600 ± 618; t-test
p < 0.01). The results demonstrated that in these serum
samples, the levels of JEV antigen-reactive IgG were
more than 10 times higher than those of DENV antigen-
reactive IgG. This suggested that the presence of DENV
cross-reactive antibodies in these participants was likely
facilitated by JE vaccination, rather than of natural
DENV infection.
Discussion
We found that the increased occurrence of DENV cross-
reactive antibodies was most pronounced in individuals
with higher levels of JEV neutralizing activity. Corres-
pondingly, the number of participants with no cross-
reactive activity to DENV exhibited lower levels of JEV
neutralizing activity. Other investigators have reported
that cross-reactive antibodies induced by JE vaccination
induced antibodies that neutralizes other flaviviruses
including WNV and DENV [9, 14], while other groups
have demonstrated the absence of neutralizing anti-
bodies to other flaviviruses immunization against JE
[15]. These studies however, used non-FcγR-expressing
cells as assay cells. Since non-FcγR-expressing cells
detects only neutralizing activity and not ADE, only
cross-reactive neutralizing activity was reported [22].
Thus, the biological relevance of cross-reactive anti-
bodies at subneutralizing levels was not determined. As
antibodies induced at sub-neutralizing levels, efficient
uptake of these virus-immune complex via the FcγR-
bearing cells can increase both the number of cells
infected and the virus yield [26, 27]. ADE assays using
FcγR-bearing cells have proved useful for functional
studies of the receptor, and in the determination of ADE
activity of human sera and for defining the role of
antibodies in DENV pathogenesis [28, 29]. In our study,
FcγR-expressing BHK cell lines detected both neutralizing
activity and ADE activity. We demonstrated that flavivirus
cross-reactive antibodies were induced after immunization,
and these subneutralizing cross-reactive antibodies en-
hanced DENV infection. Given that neutralizing antibodies
have been speculated to play a dominant role in defining
infection outcomes during the early phase of virus entry,
they may serve to block cell attachment of virus-immune
complexes to a non-FcγR-bearing cell, or inhibit virus intra-
cellular fusion after internalization [27, 30, 31]. The FcγR
may also serve a regulatory role in viral entry, and intracel-
lular fusion and virus production, by initiating cellular
responses mediated by differential Fc-effector functions,
which depends on the balance of neutralizing and ADE.
Undiluted serum samples may better reflect in vivo
conditions than the use of diluted samples [23]. In this
study, ADE activity against all four DENV serotypes was
determined by using undiluted serum samples in this
study. Of note, undiluted serum samples with high JEV
neutralizing activity titers also exhibited ADE activity to
DENV in undiluted serum samples (Table 3). Serum
dilution dilutes the amount of total antibodies, resulting
in lesser amount of cross-reactive antibody. Using con-
valescent serum samples from DENV patients, an ADE
titration curve demonstrated: (1) virus neutralization at
lower dilutions, followed by (2) ADE at higher dilutions,
and finally (3) absence of cross-reactivity at even higher
dilutions [23]. Serum samples with subneutralizing levels
of antibodies exhibited patterns of (2) and (3), in the
ADE titration curve. In this study, none of the samples
demonstrated cross-reactive neutralizing antibody to
DENV. Thus, in some undiluted serum samples that
demonstrated ADE activity, further dilution of these
samples could have further led to the decrease in, or
even absence of cross-reactive antibodies [patterns (2)
and (3)] (Table 3). Although the association between
ADE levels and severity of DENV infection needs further
clarification, previous studies have suggested that ADE
in undiluted samples confers higher viremia, which is a
prelude to severe DENV symptoms [32–34].
In mice, JE vaccination induced DENV cross-protective
immunity and virus neutralizing activity [14]. Neutralizing
activity against JEV induced by a prior JE vaccination was
also demonstrated to possess neutralizing activity against
DENV [14]. Studies have also shown that JE vaccines have
limited effect on the severity of dengue disease [35]. How-
ever, there is limited and inconclusive evidence regarding
pre-existing immunity to JEV and subsequent symptom-
atic or severe presentation of DENV infection [12, 36]. In
flavivirus infection, the ability to mount an early and vig-
orous antibody response is associated with better clinical
outcomes, indicating that anamnestic, anti-flavivirus im-
mune response induced by prior DENV and JEV infection,
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for example, is important in conferring protection, or
comparatively milder disease outcomes [37–39]. In this
study, history of past JE and yellow fever (YF) vaccine
immunization and travel history was not available. Thus,
it was not possible to conclude the contributive effects of
prior vaccination or possible exposure to flavivirus during
travel on the background immunity. Related discrepancies
due to background immunity could be attributed to the
subsequent host response to immunization and, in turn,
may have contributed to the induction of ADE activity
to DENV after immunization against JE in some of
the participants. Although there is an association with the
magnitude of ADE activity and disease severity, the
mechanisms of ADE in vivo remains elusive. Other under-
lying biological factors include cellular immunity, viral
pathogenesis, and host genetic background, all of which
are speculated to be involved in the pathogenesis of severe
dengue. In this study, we used FcγR-expressing BHK cells
to determine the levels of ADE activity in the absence of
other myeloid-specific receptors that may cooperatively
facilitate infection and mediation of innate immunity.
Presence of ADE antibodies may be one of the contribut-
ing factors to disease severity, however, subsequent studies
using FcγR and other myeloid-specific receptors would
better define the mechanisms of these antibodies in ADE-
mediated immunopathology.
The JE vaccine recipients in this study may be generally
characterized as having no prior DENV exposure (i.e.,
samples collected from a non-DENV endemic area with
an absence of DENV NA). Given that JEV continues to
co-circulate with DENV in endemic areas, samples in such
areas may demonstrate immunity to DENV which is facili-
tated by either DENV or JEV infection. In this study, the
effect of JE vaccination was determined using pre- and
post-JE vaccination samples obtained from a non-DENV
endemic area. The possibility of recent DENV infection
was excluded because all vaccinees were negative for
anti-DENV IgM antibodies, and the anti-JEV IgG titers
were comparatively higher in these vaccinees as compared
to the levels of anti-DENV IgG (Additional file 3: Table
S3). Thus, the results indicate that the DENV cross-
immunity in this study was induced by JE vaccination.
Taken together, our results support the hypothesis that
DENV cross-reactive immunity facilitated by JE vaccination
may plays two competing roles: (1) at sub-neutralizing
levels, these antibodies enhances DENV infection, poten-
tially leading to symptomatic infection and severe disease
presentation, and (2) JE vaccination elicits a flavivirus
amnestic response that is important for disease protection,
which may result in milder disease outcomes. As ADE may
reflect some aspects of DENV infection in vivo, our results
suggest the necessity of further studies on the long-
term impact of flavivirus vaccination on DENV clinical
outcomes.
Conclusions
In summary, JE vaccination induced DENV cross-
reactive antibodies, and at sub-neutralizing levels, these
antibodies demonstrated ADE to DENV. Additionally,
our study highlighted that cross-reactivity to DENV is
associated with high levels of JEV NAs and the DENV
cross-reactivity is further facilitated by JE vaccination.
Our study suggests that the immunological background
and interplay between JEV and DENV influences the
landscape of heterologous flavivirus immunity, with JE
vaccination facilitating and setting the critical threshold
of ADE and neutralizing activities of DENV cross-
reactive antibodies.
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